{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tumor+Necrosis+Factor-alpha",
    "query": {
      "condition": "Tumor Necrosis Factor-alpha"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 162,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tumor+Necrosis+Factor-alpha&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T05:16:26.523Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01369329",
      "title": "A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease",
        "IBD",
        "Colitis",
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Group 2 ustekinumab 130 mg",
          "type": "DRUG"
        },
        {
          "name": "Group 3: ustekinumab approximately 6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Group 1: Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 769,
      "start_date": "2011-07",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2016-12-07",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 67,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369329"
    },
    {
      "nct_id": "NCT00585650",
      "title": "Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo injections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-05",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 3,
      "location_summary": "Irvine, California • Winston-Salem, North Carolina • Seattle, Washington",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585650"
    },
    {
      "nct_id": "NCT01759056",
      "title": "Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "AVX 470",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avaxia Biologics, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 33,
      "start_date": "2013-02",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 9,
      "location_summary": "Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "Chesterfield",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01759056"
    },
    {
      "nct_id": "NCT00126373",
      "title": "A Trial of Wellbutrin for Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Wellbutrin (bupropion)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Altschuler, Eric, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2005-05",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2012-01-20",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126373"
    },
    {
      "nct_id": "NCT00421174",
      "title": "Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia",
        "Idiopathic Pneumonia Syndrome"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2007-08",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 12,
      "location_summary": "Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421174"
    },
    {
      "nct_id": "NCT03014518",
      "title": "Biomarkers as Predictors of Suicidal Risk in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Suicide, Attempted",
        "Suicidal Ideation",
        "Suicidal Intention",
        "Suicide"
      ],
      "interventions": [
        {
          "name": "Clinical assessments and blood samples; follow-up for 12 mos",
          "type": "OTHER"
        },
        {
          "name": "Clinical assessments and blood samples; no 12mo follow-up",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-12",
      "completion_date": "2021-06-28",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014518"
    },
    {
      "nct_id": "NCT01283971",
      "title": "A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tocilizumab [RoActemra/Actemra]",
          "type": "DRUG"
        },
        {
          "name": "adalimumab",
          "type": "DRUG"
        },
        {
          "name": "placebo to tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "placebo to adalimumab",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "folate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2011-05",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-10",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 107,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283971"
    },
    {
      "nct_id": "NCT01714726",
      "title": "Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "MEDI2070",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 121,
      "start_date": "2013-02-01",
      "completion_date": "2016-12-14",
      "has_results": true,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 26,
      "location_summary": "Encinitas, California • Los Angeles, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01714726"
    },
    {
      "nct_id": "NCT05447182",
      "title": "People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 300,
      "start_date": "2021-07-06",
      "completion_date": "2023-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05447182"
    },
    {
      "nct_id": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCAGN01876",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2017-04-25",
      "completion_date": "2021-11-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-07-23T05:16:26.523Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126110"
    }
  ]
}